These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12829200)

  • 1. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study.
    Blockmans D; Persoons P; Van Houdenhove B; Lejeune M; Bobbaers H
    Am J Med; 2003 Jun; 114(9):736-41. PubMed ID: 12829200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome.
    Peterson PK; Pheley A; Schroeppel J; Schenck C; Marshall P; Kind A; Haugland JM; Lambrecht LJ; Swan S; Goldsmith S
    Arch Intern Med; 1998 Apr; 158(8):908-14. PubMed ID: 9570178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial.
    Rowe PC; Calkins H; DeBusk K; McKenzie R; Anand R; Sharma G; Cuccherini BA; Soto N; Hohman P; Snader S; Lucas KE; Wolff M; Straus SE
    JAMA; 2001 Jan; 285(1):52-9. PubMed ID: 11150109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial.
    McKenzie R; O'Fallon A; Dale J; Demitrack M; Sharma G; Deloria M; Garcia-Borreguero D; Blackwelder W; Straus SE
    JAMA; 1998 Sep 23-30; 280(12):1061-6. PubMed ID: 9757853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
    Cleare AJ; Miell J; Heap E; Sookdeo S; Young L; Malhi GS; O'Keane V
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3545-54. PubMed ID: 11502777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers.
    Laviolle B; Donal E; Le Maguet P; Lainé F; Bellissant E
    Br J Clin Pharmacol; 2013 Feb; 75(2):423-30. PubMed ID: 22703532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.
    Annane D; Sébille V; Charpentier C; Bollaert PE; François B; Korach JM; Capellier G; Cohen Y; Azoulay E; Troché G; Chaumet-Riffaud P; Bellissant E
    JAMA; 2002 Aug; 288(7):862-71. PubMed ID: 12186604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial.
    Cleare AJ; Heap E; Malhi GS; Wessely S; O'Keane V; Miell J
    Lancet; 1999 Feb; 353(9151):455-8. PubMed ID: 9989716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.
    Hamitouche N; Comets E; Ribot M; Alvarez JC; Bellissant E; Laviolle B
    AAPS J; 2017 May; 19(3):727-735. PubMed ID: 28083797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
    Cleare AJ; O'Keane V; Miell JP
    Psychoneuroendocrinology; 2004 Jul; 29(6):724-32. PubMed ID: 15110921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between neurally mediated hypotension and the chronic fatigue syndrome.
    Bou-Holaigah I; Rowe PC; Kan J; Calkins H
    JAMA; 1995 Sep; 274(12):961-7. PubMed ID: 7674527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial.
    Asehnoune K; Seguin P; Allary J; Feuillet F; Lasocki S; Cook F; Floch H; Chabanne R; Geeraerts T; Roger C; Perrigault PF; Hanouz JL; Lukaszewicz AC; Biais M; Boucheix P; Dahyot-Fizelier C; Capdevila X; Mahe PJ; Le Maguet P; Paugam-Burtz C; Gergaud S; Plaud B; Constantin JM; Malledant Y; Flet L; Sebille V; Roquilly A;
    Lancet Respir Med; 2014 Sep; 2(9):706-16. PubMed ID: 25066331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial.
    Roerink ME; Knoop H; Bredie SJ; Heijnen M; Joosten LA; Netea MG; Dinarello CA; van der Meer JW
    Trials; 2015 Oct; 16():439. PubMed ID: 26438161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma leptin in chronic fatigue syndrome and a placebo-controlled study of the effects of low-dose hydrocortisone on leptin secretion.
    Cleare AJ; O'Keane V; Miell J
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):113-9. PubMed ID: 11453960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose hydrocortisone replacement improves wellbeing and pain tolerance in chronic pain patients with opioid-induced hypocortisolemic responses. A pilot randomized, placebo-controlled trial.
    Nenke MA; Haylock CL; Rankin W; Inder WJ; Gagliardi L; Eldridge C; Rolan P; Torpy DJ
    Psychoneuroendocrinology; 2015 Jun; 56():157-67. PubMed ID: 25827960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Otte C; Hinkelmann K; Moritz S; Yassouridis A; Jahn H; Wiedemann K; Kellner M
    J Psychiatr Res; 2010 Apr; 44(6):339-46. PubMed ID: 19909979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome.
    Arnold LM; Blom TJ; Welge JA; Mariutto E; Heller A
    Psychosomatics; 2015; 56(3):242-53. PubMed ID: 25660434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does methylphenidate reduce the symptoms of chronic fatigue syndrome?
    Blockmans D; Persoons P; Van Houdenhove B; Bobbaers H
    Am J Med; 2006 Feb; 119(2):167.e23-30. PubMed ID: 16443425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock.
    Laviolle B; Annane D; Fougerou C; Bellissant E
    Intensive Care Med; 2012 Aug; 38(8):1306-14. PubMed ID: 22584796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Fluge Ø; Rekeland IG; Lien K; Thürmer H; Borchgrevink PC; Schäfer C; Sørland K; Aßmus J; Ktoridou-Valen I; Herder I; Gotaas ME; Kvammen Ø; Baranowska KA; Bohnen LMLJ; Martinsen SS; Lonar AE; Solvang AH; Gya AES; Bruland O; Risa K; Alme K; Dahl O; Mella O
    Ann Intern Med; 2019 May; 170(9):585-593. PubMed ID: 30934066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.